Literature DB >> 465301

Ascorbate anion potentiates cytotoxicity of nitro-aromatic compounds under hypoxic and anoxic conditions.

C J Koch, R L Howell, J E Biaglow.   

Abstract

The nitro-aromatic radiosensitizing drugs are selectively toxic to hypoxic mammalian cells, and this toxicity can be greatly increased by the addition of ascorbate. The ascorbate itself is not toxic to either hypoxic or aerobic cells (as long as catalase is present to prevent the formation of significant concentrations of hydrogen peroxide) and the mixture of ascorbate plus radiosensitizer is not more toxic to aerobic cells. Sulphydryl reducing agents and dithionite have an effect opposite to ascorbate and decrease the toxicity of nitro-aromatic drugs under hypoxic conditions. Sulphydryl reducing agents are also reported to nullify the radiosensitizing properties of nitro-aromatic drugs, in contrast to ascorbate which has no effect on the radiosensitizing properties. The toxicity of nitro-aromatic drugs decreases rapidly with increasing O2 concentration. This decrease is much less rapid when ascorbate is present. The role of ascorbate in this case may be primarily as an O2 scavenger, although it is also possible that the toxic species produced by radiosensitizer-ascorbate mixtures is less easily removed or detoxified by O2.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 465301      PMCID: PMC2009878          DOI: 10.1038/bjc.1979.56

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  The effect of extreme hypoxia and glucose on the repair of potentially lethal and sublethal radiation damage by mammalian cells.

Authors:  C J Koch; J J Meneses; J W Harris
Journal:  Radiat Res       Date:  1977-06       Impact factor: 2.841

2.  Hyperthermic potentiation of cytotoxicity of Ro-07-0582 in multicell spheroids.

Authors:  R Sridhar; R Sutherland
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 May-Jun       Impact factor: 7.038

3.  Toxicity, radiation sensitivity modification, and metabolic effects of dehydroascorbate and ascorbate in mammalian cells.

Authors:  C J Koch; J E Biaglow
Journal:  J Cell Physiol       Date:  1978-03       Impact factor: 6.384

4.  Ascorbate-enhanced cytotoxicity of misonidazole.

Authors:  P D Josephy; B Palcic; L D Skarsgard
Journal:  Nature       Date:  1978-01-26       Impact factor: 49.962

5.  Cytotoxic effects of the hypoxic cell radiosensitizer Ro 7-0582 to tumor cells in vivo.

Authors:  J M Brown
Journal:  Radiat Res       Date:  1977-12       Impact factor: 2.841

6.  Testing of hypoxic cell radiosensitizers in vivo.

Authors:  A M Rauth; J Chin; L Marchow; J Paciga
Journal:  Br J Cancer Suppl       Date:  1978-06

7.  Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro.

Authors:  I J Stratford; G E Adams
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

8.  Cytotoxicity of Ro-07-0582; enhancement by hyperthermia and protection by cysteamine.

Authors:  E J Hall; M Astor; C Geard; J Biaglow
Journal:  Br J Cancer       Date:  1977-06       Impact factor: 7.640

9.  Some factors affecting the specific toxicity of misonidazole towards hypoxic mammalian cells.

Authors:  I J Stratford; P Gray
Journal:  Br J Cancer Suppl       Date:  1978-06

10.  Split dose cytotoxic experiments with misonidazole.

Authors:  I J Stratford
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

View more
  11 in total

Review 1.  Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes.

Authors:  Peter Wardman
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

2.  Hypoxic regulation of cytoglobin and neuroglobin expression in human normal and tumor tissues.

Authors:  Marwan Emara; A Robert Turner; Joan Allalunis-Turner
Journal:  Cancer Cell Int       Date:  2010-09-09       Impact factor: 5.722

3.  Expression and hypoxic up-regulation of neuroglobin in human glioblastoma cells.

Authors:  Marwan Emara; Nicole Salloum; Joan Allalunis-Turner
Journal:  Mol Oncol       Date:  2008-12-12       Impact factor: 6.603

4.  Buoyant density of EMT6 fibrosarcoma cells: time course of the density changes after growth in hypoxia.

Authors:  C E Ng; C J Koch; W R Inch
Journal:  Cell Biophys       Date:  1980-06

5.  Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours.

Authors:  M B Parliament; M J Allalunis-Turner; A J Franko; P L Olive; R Mandyam; C Santos; B Wolokoff
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

6.  Modulation of oxygen consumption rate and vascular endothelial growth factor mRNA expression in human malignant glioma cells by hypoxia.

Authors:  M J Allalunis-Turner; A J Franko; M B Parliament
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Relationship between the melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazole.

Authors:  R el Gamoussi; M D Threadgill; M Prade; I J Stratford; M Guichard
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Sulphydryls, ascorbate and oxygen as modifiers of the toxicity and metabolism of misonidazole in vitro.

Authors:  Y C Taylor; A M Rauth
Journal:  Br J Cancer       Date:  1980-06       Impact factor: 7.640

9.  Mutation in mitochondrial complex I ND6 subunit is associated with defective response to hypoxia in human glioma cells.

Authors:  Carrie DeHaan; Bahram Habibi-Nazhad; Elizabeth Yan; Nicole Salloum; Matthew Parliament; Joan Allalunis-Turner
Journal:  Mol Cancer       Date:  2004-07-12       Impact factor: 27.401

10.  Enhancing effect of pre-treatment of cells with misonidazole in hypoxia on their response to melphalan in air.

Authors:  E Smith; I J Stratford; G E Adams
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.